ADVI experts Marc Samuels, CEO and president of ADVI Health, and Lindsay Bealor Greenleaf, solution leader at ADVI, were featured in Fierce Pharma‘s article where they analyze and discuss the Inflation Reduction Act (IRA) and its long-term implications.

Marc stresses the far-reaching implications of the IRA’s Medicare Drug Price Negotiations program and expands on what this means for clients in the future, while Lindsay explains why all lines of business should be monitoring coverage and payment developments related to Medicare and Medicaid beneficiaries.

Read more on Marc and Lindsay’s insights.